文献速递生殖医学妇科

辅助生殖技术受孕儿童中的横纹肌样瘤:是否存在关联?

Rhabdoid tumors in patients conceived following ART: is there an association?
PubMed 文献 · Hum Reprod · 2023-01-01

本研究为多机构回顾性调查,比较辅助生殖技术(ART)受孕后发生的横纹肌样瘤(RT)患儿与未暴露ART的RT患儿的临床、治疗及(表观)遗传差异。结果显示RT_ART患儿女性比例显著升高、诊断中位年龄更低,其余临床、治疗、结局及分子因素与对照无显著差异,DNA甲基化分析未发现印记缺陷。

要点

  • RT_ART患儿诊断中位年龄9个月,显著低于EU-RHAB对照组的16个月(P=0.03)。
  • RT_ART组男女比2:12,女性显著占优(P=0.004)。
  • 两组在转移分期、生殖系致病性变异、生存率及DNA甲基化上均无显著差异。

核心结论

  • ART受孕后发生的RT患儿表现出显著女性优势及较低诊断中位年龄,但其他临床、治疗、结局及分子因素与未暴露ART的RT患儿无显著差异,且无印记缺陷证据。
  • 作者认为RT_ART患者的女性优势尚不明确,需要在更大的国际系列中评估。

研究设计与样本

  • 多机构回顾性调查,纳入2010年1月至2018年1月诊断的RT_ART患儿14例(EU-RHAB数据库内11/311例,数据库外3例),来自9个国家。
  • 对照为同期德国EU-RHAB队列中未暴露ART的RT患儿211例(EU-RHAB对照队列)。
  • RT_ART患儿中位随访11.5个月(范围0-120个月),EU-RHAB对照队列中位随访18.5个月(范围0-153个月)。

主要发现

  • RT_ART组诊断中位年龄9个月(范围0-66个月),显著低于EU-RHAB对照组的16个月(范围0-253个月),P=0.03。
  • RT_ART组男女比2:12,EU-RHAB对照组为116:95,P=0.004。
  • RT_ART组14例中8例为非典型畸胎样/横纹肌样瘤,3例为颅外肾外恶性横纹肌样瘤,1例为肾横纹肌样瘤,2例为同时性肿瘤;原发肿瘤位置与对照组无显著差异(P=0.27)。
  • RT_ART组14例中6例诊断时存在转移,与EU-RHAB对照组(6/14 vs 88/211)无显著差异,P=1。
  • RT_ART组12例受检者中5例存在生殖系致病性变异,与EU-RHAB对照组(5/12 vs 36/183)无显著差异,P=0.35。

局限性

  • RT为非常罕见的恶性肿瘤,本研究结果基于少量RT_ART患儿。
  • 作者指出RT_ART患者的女性优势尚不明确,需要在更大的国际系列中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: In children affected by rhabdoid tumors (RT), are there clinical, therapeutic, and/or (epi-)genetic differences between those conceived following ART compared to those conceived without ART? SUMMARY ANSWER: We detected a significantly elevated female predominance, and a lower median age at diagnosis, of children with RT conceived following ART (RT_ART) as compared to other children with RT. WHAT IS KNOWN ALREADY: Anecdotal evidence suggests an association of ART with RT. STUDY DESIGN, SIZE, DURATION: This was a multi-institutional retrospective survey. Children with RT conceived by ART were identified in our EU-RHAB database (n = 11/311 children diagnosed between January 2010 and January 2018) and outside the EU-RHAB database (n = 3) from nine different countries. A population-representative German EU-RHAB control cohort of children with RTs conceived without ART (n = 211) (EU-RHAB control cohort) during the same time period was used as a control cohort for clinical, therapeutic, and survival analyses. The median follow-up time was 11.5 months (range 0-120 months) for children with RT_ART and 18.5 months (range 0-153 months) for the EU-RHAB control cohort. PARTICIPANTS/MATERIALS, SETTING, METHODS: We analyzed 14 children with RT_ART diagnosed from January 2010 to January 2018. We examined tumors and matching blood samples for SMARCB1 mutations and copy number alterations using FISH, multiplex ligation-dependent probe amplification, and DNA sequencing. DNA methylation profiling of tumor and/or blood samples was performed using DNA methylation arrays and compared to respective control cohorts of similar age (n = 53 tumors of children with RT conceived without ART, and n = 38 blood samples of children with no tumor born small for gestational age). MAIN RESULTS AND THE ROLE OF CHANCE: The median age at diagnosis of 14 individuals with RT_ART was 9 months (range 0-66 months), significantly lower than the median age of patients with RT (n = 211) in the EU-RHAB control cohort (16 months (range 0-253), P = 0.03). A significant female predominance was observed in the RT_ART cohort (M:F ratio: 2:12 versus 116:95 in EU-RHAB control cohort, P = 0.004). Eight of 14 RT_ART patients were diagnosed with atypical teratoid rhabdoid tumor, three with extracranial, extrarenal malignant rhabdoid tumor, one with rhabdoid tumor of the kidney and two with synchronous tumors. The location of primary tumors did not differ significantly in the EU-RHAB control cohort (P = 0.27). Six of 14 RT_ART patients presented with metastases at diagnosis. Metastatic stage was not significantly different from that within the EU-RHAB control cohort (6/14 vs 88/211, P = 1). The incidence of pathogenic germline variants was five of the 12 tested RT_ART patients and, thus, not significantly different from the EU-RHAB control cohort (5/12 versus 36/183 tested, P = 0.35). The 5-year overall survival (OS) and event free survival (EFS) rates of RT_ART patients were 42.9 ± 13.2% and 21.4 ± 11%, respectively, and thus comparable to the EU-RHAB control cohort (OS 41.1 ± 3.5% and EFS 32.1 ± 3.3). We did not find other clinical, therapeutic, outcome factors distinguishing patients with RT_ART from children with RTs conceived without ART (EU-RHAB control cohort). DNA methylation analyses of 10 tumors (atypical teratoid RT = 6, extracranial, extrarenal malignant RT = 4) and six blood samples from RT_ART patients showed neither evidence of a general DNA methylation difference nor underlying imprinting defects, respectively, when compared to a control group (n = 53 RT samples of patients without ART, P = 0.51, n = 38 blood samples of patients born small for gestational age, P = 0.1205). LIMITATIONS, REASONS FOR CAUTION: RTs are very rare malignancies and our results are based on a small number of children with RT_ART. WIDER IMPLICATIONS OF THE FINDINGS: This cohort of patients with RT_ART demonstrated a marked female predominance, and a rather low median age at diagnosis even for RTs. Other clinical, treatment, outcome, and molecular factors did not differ from those conceived without ART (EU-RHAB control cohort) or reported in other series, and there was no evidence for imprinting defects. Long-term survival is achievable even in cases with pathogenic germline variants, metastatic disease at diagnosis, or relapse. The female preponderance among RT_ART patients is not yet understood and needs to be evaluated, ideally in larger international series. STUDY FUNDING/COMPETING INTEREST(S): M.C.F. is supported by the 'Deutsche Kinderkrebsstiftung' DKS 2020.10, by the 'Deutsche Forschungsgemeinschaft' DFG FR 1516/4-1 and by the Deutsche Krebshilfe 70113981. R.S. received grant support by Deutsche Krebshilfe 70114040 and for infrastructure by the KinderKrebsInitiative Buchholz/Holm-Seppensen. P.D.J. is supported by the Else-Kroener-Fresenius Stiftung and receives a Max-Eder scholarship from the Deutsche Krebshilfe. M.H. is supported by DFG (HA 3060/8-1) and IZKF Münster (Ha3/017/20). BB is supported by the 'Deutsche Kinderkrebsstiftung' DKS 2020.05. We declare no competing interests. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Nemes K, Benesch M, Kolarova J, et al. Rhabdoid tumors in patients conceived following ART: is there an association? Hum Reprod. 2023. PMID: 37553222. doi:10.1093/humrep/dead154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。